<DOC>
	<DOCNO>NCT02100176</DOCNO>
	<brief_summary>To test whether multidisciplinary intensive rehabilitation treatment ( MIRT ) slow progression disease Parkinson 's disease ( PD ) `` de novo '' patient , treated Rotigotine , randomize control study 18 month follow-up .</brief_summary>
	<brief_title>MIRT Rotigotine Early Stage PD</brief_title>
	<detailed_description>In last year different rehabilitation treatment propose address specific motor deficit Parkinson 's disease . Nevertheless , evidence possible neuroprotective action exercise PD obscure fact study perform patient different disease stage variety pharmacological treatment . Our objective test whether multidisciplinary intensive rehabilitation treatment ( MIRT ) slow progression disease PD `` de novo '' patient , treated Rotigotine , randomize control study 18 month follow-up . 40 Patients initial stage PD ( H &amp; Y stag 1,5-2 ) treat Rotigotine enrol randomly assigne two group . Patients group 1 ( 20 subject ) undergo 2 MIRT cycle ( T0 T3 ) . MIRT consist 4-week cycle physiotherapy entail three daily session 5 day week ( Frazzitta G. et al. , Neurorehabilitation [ 30 ] 2012 , 295-301 ) . Patients Group 2 ( 20 subject ) continue drug therapy alone . For group 1 , Unified Parkinson 's disease rating scale ( UPDRS ) II , UPDRS III , six-minute walk test ( 6MWT ) , Berg Balance Scale ( BBS ) , Timed-up-and-go test ( TUG ) , comfortable fast gait speed , Self-assessment Parkinson 's disease disability scale L-dopa equivalent assess Baseline T0 , T1 ( discharge first MIRT cycle ) , T2 ( control 6 month discharge ) , T3 ( hospitalization second MIRT cycle ) , T4 ( discharge second MIRT cycle ) T5 ( end protocol , 18 month ) ; For group 2 , UPDRS II , UPDRS III , six-minute walk test ( 6MWT ) , Berg Balance Scale ( BBS ) , Timed-up-and-go test ( TUG ) , confortable fast gait speed , Self-assessment Parkinson 's disease disability scale L-dopa equivalent assess Baseline T0 , T1 ( check-up 6 month ) , T2 ( check-up 12 month ) , T3 ( check-up 18 month ) .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<mesh_term>Dopamine Agonists</mesh_term>
	<criteria>Idiopathic Parkinson 's disease accord Gelb et al. , ability walk without physical assistance , cognitive impairment ( MMSE score &gt; 26 ) , comorbidity unrelated Parkinson 's disease , vestibular/visual dysfunction limit locomotor balance . Atypical Parkinsonisms , cognitive impairment ( MMSE &lt; 26 ) , comorbidities relate PD , vestibular/visual dysfunction limit locomotor balance .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Rehabilitation treatment</keyword>
</DOC>